Setanaxib (also known as GKT-137831; GTK831) is a novel, specific, potent, orally bioavailable, and dual inhibitor of NADPH oxidase NOX1/NOX4 with Ki of 110 nM and 140 nM, respectively.

VAS 2870 is a NADPH oxidase (Nox) inhibitor that enhances TGF-β-induced apoptosis of liver tumor cells.

GSK2795039 is a novel and potent small molecule NADPH oxidase 2 inhibitor with a mean pIC50 of 6 in different cell-free assays.

GKT136901 is a novel and potent NOX1/4 inhibitor acting by blocking tumor angiogenesis through a PPARα mediated mechanism and selective scavenging of peroxynitrite (PON).

GLX351322 is a new NOX4 (NADPH oxidase 4) inhibitor which has relative NOX4 selectivity over NOX2 with with an IC50 of 5 μ M inhibiting hydrogen peroxide production from NOX4-overexpressing cells.

APX-115, also known as EWHA 18278,is a novel,potent, orally active pan NADPH oxidase (Nox) inhibitor with Ki values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively.